<DOC>
	<DOCNO>NCT02535507</DOCNO>
	<brief_summary>Various driver gene mutation identify lung cancer . Among , human epidermal growth factor 2 ( HER2 ) identify approximately 2 % non-small cell lung cancers.Pyrotinib oral tyrosine kinase inhibitor target HER-1 HER-2 receptor . This study design evaluate efficacy safety Pyrotinib patient HER2 positive advance Non-small cell lung cancer .</brief_summary>
	<brief_title>Efficacy Safety Pyrotinib Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This study design evaluate efficacy safety Pyrotinib patient HER2 positive advance pre-treated Non-small cell lung cancer . To observe objective response rate ( ORR ) pyrotinib HER2 positive NSCLC . To observe Progression free survival （PFS） . To assess overall survival ( OS ) . To assess side effect . To evaluate quality life . To explore relationship biomarkers toxicity/efficacy Pyrotinib .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Aged ≥18 ≤80 year . ECOG performance status 0 1 . Life expectancy 12 week . At least one measurable lesion exists . ( RECIST 1.1 ) Histologically cytologic confirm HER2 positive advance Nonsmall cell lung cancer fail prior therapy . Required laboratory value include follow parameter : ANC : ≥ 1.5 x 10^9/L , Platelet count : ≥ 80 x 10^9/L , Hemoglobin : ≥ 90 g/L , Total bilirubin : ≤ 1.5 x upper limit normal , ULN , ALT AST : ≤ 1.5 x ULN , BUN creatine clearance rate : ≥ 50 mL/min LVEF : ≥ 50 % QTcF : &lt; 470 m Signed informed consent . Subjects third space fluid control drainage method . Subjects unable swallow tablet , dysfunction gastrointestinal absorption . Less 4 week last radiotherapy , chemotherapy , target therapy Subjects uncontrolled hypokalemia hypomagnesemia study entry . Subjects interrupt use drug may cause QT prolongation study . Receiving antitumor therapy . Known history hypersensitivity pyrotinib component . Ongoing infection ( determined investigator ) . History immunodeficiency , include HIVpositive , suffer acquire , congenital immunodeficiency disease , history organ transplantation . Subjects heart disease , include : ( 1 ) angina ; ( 2 ) require medication clinically significant arrhythmia ; ( 3 ) myocardial infarction ; ( 4 ) heart failure ; ( 5 ) Any heart disease judge investigator unsuitable participate trial . Female patient pregnancy , lactation woman childbearing potential test positive baseline pregnancy test . Known history neurological psychiatric disease , include epilepsy dementia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>pyrotinib</keyword>
	<keyword>HER2</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>Phase II</keyword>
</DOC>